Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $77.00 price target on the biotechnology company’s stock.

Separately, Cantor Fitzgerald raised their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $13.59 on Tuesday. The firm has a market cap of $617.94 million, a P/E ratio of -12.82 and a beta of 4.08. The firm’s 50 day moving average price is $14.37 and its 200-day moving average price is $13.93. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at $462,000. Voloridge Investment Management LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $1,678,000. Woodline Partners LP purchased a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $8,693,000. Two Sigma Investments LP boosted its position in shares of Capricor Therapeutics by 223.6% in the 4th quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company’s stock valued at $1,643,000 after purchasing an additional 82,254 shares during the period. Finally, Rafferty Asset Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth approximately $1,743,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.